1. Home
  2. DMAC vs RIGL Comparison

DMAC vs RIGL Comparison

Compare DMAC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • RIGL
  • Stock Information
  • Founded
  • DMAC 2000
  • RIGL 1996
  • Country
  • DMAC United States
  • RIGL United States
  • Employees
  • DMAC N/A
  • RIGL N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMAC Health Care
  • RIGL Health Care
  • Exchange
  • DMAC Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • DMAC 310.1M
  • RIGL 335.5M
  • IPO Year
  • DMAC N/A
  • RIGL 2000
  • Fundamental
  • Price
  • DMAC $6.87
  • RIGL $34.22
  • Analyst Decision
  • DMAC Strong Buy
  • RIGL Buy
  • Analyst Count
  • DMAC 3
  • RIGL 5
  • Target Price
  • DMAC $12.33
  • RIGL $38.20
  • AVG Volume (30 Days)
  • DMAC 448.5K
  • RIGL 710.9K
  • Earning Date
  • DMAC 11-12-2025
  • RIGL 11-06-2025
  • Dividend Yield
  • DMAC N/A
  • RIGL N/A
  • EPS Growth
  • DMAC N/A
  • RIGL N/A
  • EPS
  • DMAC N/A
  • RIGL 5.43
  • Revenue
  • DMAC N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • DMAC N/A
  • RIGL $59.93
  • Revenue Next Year
  • DMAC N/A
  • RIGL N/A
  • P/E Ratio
  • DMAC N/A
  • RIGL $6.33
  • Revenue Growth
  • DMAC N/A
  • RIGL 105.62
  • 52 Week Low
  • DMAC $3.19
  • RIGL $13.37
  • 52 Week High
  • DMAC $7.49
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 63.84
  • RIGL 43.91
  • Support Level
  • DMAC $6.83
  • RIGL $35.56
  • Resistance Level
  • DMAC $7.41
  • RIGL $38.72
  • Average True Range (ATR)
  • DMAC 0.43
  • RIGL 2.19
  • MACD
  • DMAC 0.03
  • RIGL -1.19
  • Stochastic Oscillator
  • DMAC 73.62
  • RIGL 2.97

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: